Facial fat transfer evidence is often reduced to an appealing phrase: use a person’s own fat to restore a softer, fuller face. Autologous fat transfer (also called fat grafting, lipofilling or lipotransfer) does use fat harvested from one area of the body and placed in selected facial planes. It can help address certain contour deficits, age-related volume change or asymmetry. But it is not a predictable syringe of “permanent filler.” Some transferred fat establishes a blood supply and survives; some is resorbed. The proportion that remains, and the way it looks in a particular facial compartment, varies enough that no responsible clinician can promise a fixed final volume.
This review of facial fat transfer evidence explains what published research can and cannot tell a prospective patient about retention, planned overcorrection, safety and selection. It is not a personal treatment recommendation. A facial assessment must consider skin quality, baseline fat distribution, skeletal support, asymmetry, prior procedures, weight stability, medical history and the person’s reasons for seeking change. It should also include the reasonable option to wait or not have a procedure.
What facial fat transfer is designed to do
In a typical procedure, a surgeon harvests a small amount of a patient’s own fat—commonly from the abdomen, flanks or thighs—then processes it and injects it in small parcels into planned facial layers. The goal is three-dimensional contour change rather than simply making every facial line disappear. Depending on the anatomy and indication, treated areas may include the temples, cheeks, tear-trough or infraorbital transition, nasolabial region, lips, chin or scars. Reconstructive uses, such as correcting volume loss after trauma or congenital conditions, are not the same clinical problem as elective facial rejuvenation; their outcomes should not be treated as interchangeable.
“Natural” in this context does not mean risk-free or automatically suitable. The material is autologous, so there is no manufactured filler product left in the face, but harvesting and injection are still invasive steps. Outcome depends on anatomy, how much volume is needed, the recipient tissue, the handling and placement of the graft, and healing. A facial fat transfer cannot reliably tighten markedly loose skin, lift descended tissues, change facial bone width or correct every cause of a hollow, shadow or asymmetry.
That distinction matters when comparing volume restoration with tissue repositioning. A person whose concern is mainly laxity may need a different discussion from someone with a local volume deficit. The patient-centred tools explained in our guide to validated surgical outcome measures, including FACE-Q can help separate a meaningful, individual goal from a vague promise of a universally better face.
Retention: a useful estimate is not an individual forecast
Retention means the portion of the transferred volume that remains after early healing and resorption have progressed. It is one of the most important outcomes in facial fat transfer, yet it is difficult to compare across studies. Research has used different donor sites, harvesting and processing methods, injection planes, facial regions, injected volumes, indications, follow-up periods and measurement tools. Photographs, clinical judgement, three-dimensional surface imaging, ultrasound, CT and MRI do not measure exactly the same thing. An attractive before-and-after image also cannot distinguish retained graft volume from lighting, swelling, weight change, camera angle or normal soft-tissue change.
A 2021 systematic review and meta-analysis of 27 studies involving 1,011 patients found objectively measured retention ranging from 26% to 83% over mean follow-up periods of 3 to 24 months. Its pooled estimate was 47% (95% confidence interval 41% to 53%), and the authors concluded that the exact retained percentage remains unpredictable. This is a valuable benchmark, but it must not be converted into a promise that every patient will keep “about half” of every injected millilitre. A pooled average describes a heterogeneous set of studies, not a prescription for one cheek, temple or tear trough.
An earlier systematic review of 43 facial-fat-grafting studies reported a mean weighted retention of 41.63% at a mean 13.9 months for non-enriched grafts. A separate review limited to three-dimensional imaging found a broad 21% to 82.3% range across ten studies. Such variation is not a reason to dismiss the procedure; it is a reason to be precise about uncertainty. It also explains why planned volume, the number of sessions and the discussion of possible under-correction need to be individualised.
Why volume changes in the first months
Immediately after treatment, the face can look fuller than its eventual settled state because of injected volume, local fluid and swelling. During healing, a proportion of transplanted cells may survive while another proportion is resorbed. Retention measurements in clinical studies commonly decline during the early follow-up period and then tend to become more stable, but the timing and apparent endpoint differ by study and facial site. There is no universal calendar on which every patient’s face has a final result.
Location matters. A small, sharply defined region and a broad cheek compartment do not have the same tissue environment or visual tolerance for change. Baseline asymmetry matters as well: equal injected quantities may not produce equal-looking sides, while intentionally unequal quantities may be clinically appropriate. Weight gain or loss can further change the appearance of facial adipose tissue after surgery. These factors are why a single advertised retention percentage, a fixed volume chart or another person’s social-media result is a poor basis for planning.
Research has explored whether harvesting, washing, centrifugation, filtration, sedimentation, enrichment methods and injection technique improve survival. Some studies suggest differences, but the three-dimensional-imaging review found no significant overall difference among the principal processing approaches despite trends in individual reports. Newer ultrasound-assisted literature is promising for measurement and safety guidance, not proof that one branded method can guarantee survival. In practical terms, a surgeon should be able to explain the method used and its rationale without claiming that technique removes biologic variability.
Overcorrection: why it is a judgement call, not a formula
Because some loss of volume is expected, a surgeon may plan a degree of initial fullness. This is sometimes described as overcorrection. The word can be misleading: it should not mean placing the largest possible amount of fat in the hope that “some will disappear.” Excess volume in a delicate facial area can create a heavy, puffy, irregular or asymmetric appearance. It can also make it harder to distinguish early swelling from a contour problem, particularly when photographs are taken too soon.
The safe amount of planned initial fullness is not standardised. It depends on the area being treated, tissue capacity, skin thickness, starting asymmetry, the desired change and a surgeon’s assessment of how the graft can be layered. Published three-dimensional-imaging studies have reported overcorrection among recorded complications, and other reviews identify asymmetry and irregular distribution among the more frequent non-catastrophic concerns. These observations support conservative, compartment-specific placement; they do not create a universal volume rule.
Under-correction is possible too. A patient should understand before surgery that a staged approach or a later touch-up may sometimes be discussed, while also understanding that a second procedure has its own cost, recovery and uncertainty. Conversely, correcting too much fullness can be more complicated than adding modest volume. Depending on the cause and timing, management may involve observation, allowing swelling to resolve, revision planning or a different treatment; none can recreate a pre-procedure facial state with certainty.
What the safety literature says—and why anatomy is central
Most reported adverse events in larger outcome series are minor, but “usually uncomplicated” must never be translated as “harmless.” Systematic reviews of facial fat grafting have reported bruising or haematoma, swelling, irregularity, asymmetry, prolonged oedema, infection, fat necrosis or oil cysts, altered sensation and the need for further correction. How often these occur is difficult to compare because studies differ in patient selection, follow-up and reporting. Low reported event rates can also miss delayed or unreported outcomes.
Rare vascular complications deserve explicit discussion even though they are not the usual outcome. A 2024 systematic review of published serious complications after aesthetic facial autologous fat grafting identified reports of permanent or severe events, including vision loss, stroke-like neurological injury and skin necrosis. The cases in that review were concentrated particularly in the forehead and temporal regions. Case reports do not provide an individual probability, and they should not be used to frighten patients with a fictional certainty. They do show why knowledge of vascular anatomy, appropriate cannula and injection technique, careful patient selection and a clinician equipped to recognise and respond to complications are essential. The same evidence-first approach to discussing uncommon harm is used in our review of rhinoplasty complications and risk.
Patients should receive clear postoperative contact instructions from their treating team. Increasing one-sided swelling, escalating pain, fever, spreading redness, pus or unusual drainage, a new change in vision, severe headache, new weakness, confusion, speech difficulty or breathing difficulty should not be assessed through a website; prompt contact with the treating clinician and urgent local assessment when appropriate are important. The exact advice depends on the procedure, timing and symptoms.
Who needs an especially careful selection conversation?
Good candidacy is not decided by age alone or by a filtered photograph. People with untreated medical conditions, active infection, a tendency to problematic scarring, bleeding-risk medicines, nicotine exposure, substantial recent or planned weight change, previous facial fillers or surgery, or marked baseline asymmetry need individual assessment. So do people seeking a dramatic face-shape change when their concern is primarily bone, skin laxity or another structural layer that fat transfer cannot correct.
Expectation quality is equally important. A person may reasonably want softer temples, improved symmetry or less visible volume loss. It is less realistic to ask for a permanent, perfectly even face that never changes with aging or weight. Validated patient-reported measures, including modules from the FACE-Q Aesthetics programme, can capture how patients perceive outcomes, but even high satisfaction scores do not erase variability in retention or establish that a result is right for every person.
A decision should be unpressured and informed by examination, standardised photographs where appropriate, alternatives and time to reflect. The broader framework in our article on informed consent, risk and uncertainty in elective surgery is relevant: consent is a conversation about what might happen, what might not happen and what the alternatives are—not a signature attached to a guaranteed result.
Questions worth asking at a facial fat transfer consultation
- What is causing the contour concern in my face: local volume loss, tissue descent, bone shape, skin laxity, weight change or asymmetry?
- Which facial areas would be treated, in which planes, and what change is realistic for each area?
- How do you measure and discuss retention, and why should that estimate not be treated as a personal guarantee?
- Is conservative treatment or a staged plan more appropriate than trying to achieve the whole goal in one session?
- What would under-correction, overcorrection, irregularity or asymmetry look like in my case, and what options would exist if they occurred?
- What rare vascular risks are relevant to the areas proposed, and what safety protocols and emergency arrangements are in place?
- How will follow-up be organised, especially if I will be away from the treating clinic?
For a practical patient-facing introduction, see our facial fat transfer guide. The site’s facial fat transfer operation page outlines the procedure pathway. Neither page can determine candidacy, predict retained volume or replace a direct consultation with an appropriately qualified clinician.
Limits of the evidence
The evidence base has meaningful strengths—systematic reviews, growing use of three-dimensional assessment and studies across reconstructive and aesthetic indications—but it also has important limits. Much of the literature consists of observational series rather than large, blinded comparative trials. Definitions of “retention,” “success,” “complication” and “final follow-up” vary. Many studies mix facial regions, indications and techniques, and patient satisfaction is influenced by expectation, selection and the quality of counselling. Rare severe events are often represented by case reports, which identify possible harms but cannot calculate an individual risk.
For these reasons, current facial fat transfer evidence supports a balanced conclusion: the procedure can be a useful tool for selected facial volume concerns, but it cannot promise a permanent percentage of volume, perfectly symmetric contour or a procedure without risk. A careful plan uses anatomy, restraint, transparent discussion of resorption and a follow-up strategy—not a marketing claim about “natural permanent filler.”
Bottom line
Facial fat transfer may restore volume or improve selected contour deficits, but the biology of graft survival remains variable. The best pooled studies offer context, not certainty: retention estimates vary widely according to patient, facial site, technique, measurement and follow-up. Planned fullness may be reasonable in expert hands, while indiscriminate overcorrection is not. The most defensible decision is one based on a realistic goal, conservative anatomy-led treatment and a clear understanding that both the benefits and the limits of facial fat grafting are individual.
